세계의 의료용 아이소토프 시장 규모, 점유율 및 동향 분석 보고서 : 유형별, 최종사용자별, 용도별, 지역별 전망 및 예측(2023-2030년)

The Global Medical Isotope Market size is expected to reach $9.1 billion by 2030, rising at a market growth of 8.6% CAGR during the forecast period.

The development of new therapeutic radiopharmaceuticals and expanded clinical indications for existing isotopes has led to a growing number of therapeutic procedures in nuclear medicine. Consequently, the nuclear therapy segment would generate approximately 24.2 % share of the market by 2030. Research and clinical trials continue to explore the efficacy and safety of isotopic therapies for a wide range of medical conditions, including bone metastases, neuroendocrine tumors, thyroid disorders, and hematological malignancies.

Nuclear medicine imaging technology advances have significantly improved image quality, resolution, and sensitivity. High-resolution imaging systems, such as PET/CT and SPECT/CT scanners, provide detailed anatomical and functional information, allowing healthcare professionals to visualize physiological processes at the molecular level with exceptional clarity. Therefore, advancements in nuclear medicine imaging techniques drive the market's growth.

Additionally, Cancer and cardiovascular diseases often require comprehensive diagnostic evaluation to assess disease extent, stage, and progression. Medical isotopes, such as technetium-99m (Tc-99m) and fluorine-18 (F-18), are widely used in nuclear medicine imaging techniques such as PET and single-photon emission computed tomography (SPECT) to visualize physiological processes and identify disease-related abnormalities. Therefore, the rising cases of cancer and cardiovascular diseases are driving the growth of the market.

However, Many radioisotopes used in nuclear medicine imaging and therapy are produced in nuclear reactors, which require highly specialized infrastructure and regulatory oversight. Radioisotope availability depends on the operational status of nuclear reactors, which may be subject to maintenance shutdowns, regulatory inspections, and safety protocols. Hence, the limited availability of radioisotopes is hampering the market's growth.

Furthermore, Restrictions on travel, lockdown measures, and reduced staffing at nuclear reactors and isotope production facilities led to delays and shortages in the availability of medical isotopes, impacting patient care and diagnostic procedures. During the peak of the pandemic, many non-essential medical procedures, including diagnostic imaging and nuclear medicine scans, were postponed, or canceled to prioritize resources for COVID-19 patients. Thus, the COVID-19 pandemic had a negative impact on the market.

By Type Analysis

On the basis of type, the market is segmented into stable isotopes and radioisotopes. The radioisotopes segment recorded the 73.57 % revenue share in the market in 2022. Radioisotopes, drugs, or compounds labeled with radioactive isotopes for diagnostic purposes are essential for radiopharmaceuticals. Radioisotopes such as technetium-99m (Tc-99m), gallium-68 (Ga-68), and copper-64 (Cu-64) are commonly incorporated into radiopharmaceutical formulations for clinical use. Hence, higher demand for radiopharmaceuticals is driving the growth of the segment.

By End User Analysis

Based on end user, the market is categorized into hospitals, diagnostic centers, and research institutes. The diagnostic centers segment witnessed a 28.92 % revenue share in the market in 2022. Diagnostic centers facilitate multidisciplinary collaboration among healthcare professionals, including radiologists, nuclear medicine physicians, oncologists, surgeons, and medical physicists. Diagnostic centers are hubs for collaboration and communication, fostering teamwork and care coordination across different specialties.

By Application Analysis

Based on application, the market is bifurcated into diagnostic and nuclear therapy. The diagnostic segment attained the 75.79 % revenue share in the market in 2022. Diagnostic imaging plays a crucial role in the early detection and diagnosis of various medical conditions, including cancer, cardiovascular diseases, neurological disorders, and musculoskeletal injuries. Medical isotopes enable the development of highly sensitive and specific imaging techniques that facilitate the early detection of abnormalities and disease processes at the cellular and molecular levels.

By Regional Analysis

Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the Asia Pacific region generated a 26.87 % revenue share in the market. The Asia Pacific region is experiencing a rise in the incidence of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions. As the burden of disease increases, there is a greater need for early detection, accurate diagnosis, and effective treatment options, driving demand for diagnostic imaging studies and therapeutic interventions using medical isotopes.

Recent Strategies Deployed in the Market

• Feb-2024: Bayer AG has entered into an agreement with PanTera, a Belgian Joint Venture established by IBA and SCK CEN. As per the agreement, PanTera will provide actinium-225 to Bayer, allowing Bayer to continue its clinical trials.
• Jan-2024: ITM Isotope Technologies Munich SE has entered into a supply agreement with Alpha-9 Oncology, Inc., a clinical-stage biotechnology company focused on developing unique radiopharmaceuticals. As per the agreement, ITM will provide its medical radioisotopes, specifically non-carrier-added Lutetium-177 (n.c.a.177LU), to support Alpha-9's development of Lutetium-based candidates for radiopharmaceutical therapy aimed at treating cancer. This collaboration contributes to the advancement of Alpha-9's pipeline candidate for cancer treatment through the utilization of ITM's radioisotope technology.
• Oct-2023: Canadian Nuclear Laboratories (CNL) has established a joint venture with ITM Isotope Technologies Munich SE, a prominent radiopharmaceutical biotech company, under the name Actineer Inc. The objective of this new venture is to expand the industrial production capacity of actinium-225 and address the global demand for this highly sought-after radioisotope, which remains underserved in terms of manufacturing and production capabilities.
• Feb-2023: Canadian Nuclear Laboratories (CNL) has collaborated with Jubilant Radiopharma, a global leader in radiopharmaceuticals, to collaborate on the advancement of innovative alpha radiopharmaceuticals. This collaboration aims to jointly develop groundbreaking radiopharmaceutical therapies. Operating under CNL's Canadian Nuclear Research Initiative - Health (CNRI-H) program, this joint program represents a significant step in CNL's broader initiative to foster the exploration and creation of new, life-saving radiopharmaceutical treatments. This includes the exploration of targeted alpha therapy and novel cancer treatments utilizing Actinium-225, a medical isotope manufactured by CNL.
• Nov-2022: Eczacibasi-Monrol has entered into a partnership with FutureChem Co., Ltd., a South Korea-based company specializing in the development and distribution of radiopharmaceuticals. Under this agreement, Eczacibasi-Monrol will supply the radioisotope Lu-177 n.c.a. (Lutetium-177 non-carrier-added) to support FutureChem's Investigational New Drug (IND)-enabling Phase 2 clinical trial with Ludotadipep, 177Lu-FC705.

List of Key Companies Profiled

• Mallinckrodt PLC
• Bayer AG
• GE HealthCare Technologies, Inc.
• Canadian Nuclear Laboratories (Atomic Energy Of Canada Limited)
• ITM Isotope Technologies Munich SE
• Siemens Healthineers AG
• Eczacibasi-Monrol
• NorthStar Medical Radioisotopes, LLC
• Nordion Inc. (Sotera Health LLC)
• Iba SA

Global Medical Isotope Market Report Segmentation

By Type

• Radioisotopes
• Stable Isotopes

By End User

• Hospitals
• Diagnostic Centers
• Research Institutes

By Application

• Diagnostic
• Nuclear Therapy

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1.Market Scope & Methodology

• 1.1Market Definition
• 1.2Objectives
• 1.3Market Scope
• 1.4Segmentation
  • 1.4.1Global Medical Isotope Market, by Type
  • 1.4.2Global Medical Isotope Market, by End User
  • 1.4.3Global Medical Isotope Market, by Application
  • 1.4.4Global Medical Isotope Market, by Geography
• 1.5Methodology for the research

Chapter 2.Market at a Glance

• 2.1Key Highlights

Chapter 3.Market Overview

• 3.1Introduction
  • 3.1.1Overview
    • 3.1.1.1Market Composition and Scenario
• 3.2Key Factors Impacting the Market
  • 3.2.1Market Drivers
  • 3.2.2Market Opportunities
  • 3.2.3Market Restraints
  • 3.2.4Market Challenges
• 3.3Porter's Five Forces Analysis

Chapter 4.Recent Strategies Deployed in Medical Isotopes Market

Chapter 5.Global Medical Isotope Market by Type

• 5.1Global Radioisotopes Market by Region
• 5.2Global Stable Isotopes Market by Region

Chapter 6.Global Medical Isotope Market by End User

• 6.1Global Hospitals Market by Region
• 6.2Global Diagnostic Centers Market by Region
• 6.3Global Research Institutes Market by Region

Chapter 7.Global Medical Isotope Market by Application

• 7.1Global Diagonostic Market by Region
• 7.2Global Nuclear Therapy Market by Region

Chapter 8.Global Medical Isotope Market by Region

• 8.1North America Medical Isotope Market
  • 8.1.1North America Medical Isotope Market by Type
    • 8.1.1.1North America Radioisotopes Market by Region
    • 8.1.1.2North America Stable Isotopes Market by Region
  • 8.1.2North America Medical Isotope Market by End User
    • 8.1.2.1North America Hospitals Market by Country
    • 8.1.2.2North America Diagnostic Centers Market by Country
    • 8.1.2.3North America Research Institutes Market by Country
  • 8.1.3North America Medical Isotope Market by Application
    • 8.1.3.1North America Diagonostic Market by Country
    • 8.1.3.2North America Nuclear Therapy Market by Country
  • 8.1.4North America Medical Isotope Market by Country
    • 8.1.4.1US Medical Isotope Market
      • 8.1.4.1.1US Medical Isotope Market by Type
      • 8.1.4.1.2US Medical Isotope Market by End User
      • 8.1.4.1.3US Medical Isotope Market by Application
    • 8.1.4.2Canada Medical Isotope Market
      • 8.1.4.2.1Canada Medical Isotope Market by Type
      • 8.1.4.2.2Canada Medical Isotope Market by End User
      • 8.1.4.2.3Canada Medical Isotope Market by Application
    • 8.1.4.3Mexico Medical Isotope Market
      • 8.1.4.3.1Mexico Medical Isotope Market by Type
      • 8.1.4.3.2Mexico Medical Isotope Market by End User
      • 8.1.4.3.3Mexico Medical Isotope Market by Application
    • 8.1.4.4Rest of North America Medical Isotope Market
      • 8.1.4.4.1Rest of North America Medical Isotope Market by Type
      • 8.1.4.4.2Rest of North America Medical Isotope Market by End User
      • 8.1.4.4.3Rest of North America Medical Isotope Market by Application
• 8.2Europe Medical Isotope Market
  • 8.2.1Europe Medical Isotope Market by Type
    • 8.2.1.1Europe Radioisotopes Market by Country
    • 8.2.1.2Europe Stable Isotopes Market by Country
  • 8.2.2Europe Medical Isotope Market by End User
    • 8.2.2.1Europe Hospitals Market by Country
    • 8.2.2.2Europe Diagnostic Centers Market by Country
    • 8.2.2.3Europe Research Institutes Market by Country
  • 8.2.3Europe Medical Isotope Market by Application
    • 8.2.3.1Europe Diagonostic Market by Country
    • 8.2.3.2Europe Nuclear Therapy Market by Country
  • 8.2.4Europe Medical Isotope Market by Country
    • 8.2.4.1Germany Medical Isotope Market
      • 8.2.4.1.1Germany Medical Isotope Market by Type
      • 8.2.4.1.2Germany Medical Isotope Market by End User
      • 8.2.4.1.3Germany Medical Isotope Market by Application
    • 8.2.4.2UK Medical Isotope Market
      • 8.2.4.2.1UK Medical Isotope Market by Type
      • 8.2.4.2.2UK Medical Isotope Market by End User
      • 8.2.4.2.3UK Medical Isotope Market by Application
    • 8.2.4.3France Medical Isotope Market
      • 8.2.4.3.1France Medical Isotope Market by Type
      • 8.2.4.3.2France Medical Isotope Market by End User
      • 8.2.4.3.3France Medical Isotope Market by Application
    • 8.2.4.4Russia Medical Isotope Market
      • 8.2.4.4.1Russia Medical Isotope Market by Type
      • 8.2.4.4.2Russia Medical Isotope Market by End User
      • 8.2.4.4.3Russia Medical Isotope Market by Application
    • 8.2.4.5Spain Medical Isotope Market
      • 8.2.4.5.1Spain Medical Isotope Market by Type
      • 8.2.4.5.2Spain Medical Isotope Market by End User
      • 8.2.4.5.3Spain Medical Isotope Market by Application
    • 8.2.4.6Italy Medical Isotope Market
      • 8.2.4.6.1Italy Medical Isotope Market by Type
      • 8.2.4.6.2Italy Medical Isotope Market by End User
      • 8.2.4.6.3Italy Medical Isotope Market by Application
    • 8.2.4.7Rest of Europe Medical Isotope Market
      • 8.2.4.7.1Rest of Europe Medical Isotope Market by Type
      • 8.2.4.7.2Rest of Europe Medical Isotope Market by End User
      • 8.2.4.7.3Rest of Europe Medical Isotope Market by Application
• 8.3Asia Pacific Medical Isotope Market
  • 8.3.1Asia Pacific Medical Isotope Market by Type
    • 8.3.1.1Asia Pacific Radioisotopes Market by Country
    • 8.3.1.2Asia Pacific Stable Isotopes Market by Country
  • 8.3.2Asia Pacific Medical Isotope Market by End User
    • 8.3.2.1Asia Pacific Hospitals Market by Country
    • 8.3.2.2Asia Pacific Diagnostic Centers Market by Country
    • 8.3.2.3Asia Pacific Research Institutes Market by Country
  • 8.3.3Asia Pacific Medical Isotope Market by Application
    • 8.3.3.1Asia Pacific Diagonostic Market by Country
    • 8.3.3.2Asia Pacific Nuclear Therapy Market by Country
  • 8.3.4Asia Pacific Medical Isotope Market by Country
    • 8.3.4.1China Medical Isotope Market
      • 8.3.4.1.1China Medical Isotope Market by Type
      • 8.3.4.1.2China Medical Isotope Market by End User
      • 8.3.4.1.3China Medical Isotope Market by Application
    • 8.3.4.2Japan Medical Isotope Market
      • 8.3.4.2.1Japan Medical Isotope Market by Type
      • 8.3.4.2.2Japan Medical Isotope Market by End User
      • 8.3.4.2.3Japan Medical Isotope Market by Application
    • 8.3.4.3India Medical Isotope Market
      • 8.3.4.3.1India Medical Isotope Market by Type
      • 8.3.4.3.2India Medical Isotope Market by End User
      • 8.3.4.3.3India Medical Isotope Market by Application
    • 8.3.4.4South Korea Medical Isotope Market
      • 8.3.4.4.1South Korea Medical Isotope Market by Type
      • 8.3.4.4.2South Korea Medical Isotope Market by End User
      • 8.3.4.4.3South Korea Medical Isotope Market by Application
    • 8.3.4.5Singapore Medical Isotope Market
      • 8.3.4.5.1Singapore Medical Isotope Market by Type
      • 8.3.4.5.2Singapore Medical Isotope Market by End User
      • 8.3.4.5.3Singapore Medical Isotope Market by Application
    • 8.3.4.6Malaysia Medical Isotope Market
      • 8.3.4.6.1Malaysia Medical Isotope Market by Type
      • 8.3.4.6.2Malaysia Medical Isotope Market by End User
      • 8.3.4.6.3Malaysia Medical Isotope Market by Application
    • 8.3.4.7Rest of Asia Pacific Medical Isotope Market
      • 8.3.4.7.1Rest of Asia Pacific Medical Isotope Market by Type
      • 8.3.4.7.2Rest of Asia Pacific Medical Isotope Market by End User
      • 8.3.4.7.3Rest of Asia Pacific Medical Isotope Market by Application
• 8.4LAMEA Medical Isotope Market
  • 8.4.1LAMEA Medical Isotope Market by Type
    • 8.4.1.1LAMEA Radioisotopes Market by Country
    • 8.4.1.2LAMEA Stable Isotopes Market by Country
  • 8.4.2LAMEA Medical Isotope Market by End User
    • 8.4.2.1LAMEA Hospitals Market by Country
    • 8.4.2.2LAMEA Diagnostic Centers Market by Country
    • 8.4.2.3LAMEA Research Institutes Market by Country
  • 8.4.3LAMEA Medical Isotope Market by Application
    • 8.4.3.1LAMEA Diagonostic Market by Country
    • 8.4.3.2LAMEA Nuclear Therapy Market by Country
  • 8.4.4LAMEA Medical Isotope Market by Country
    • 8.4.4.1Brazil Medical Isotope Market
      • 8.4.4.1.1Brazil Medical Isotope Market by Type
      • 8.4.4.1.2Brazil Medical Isotope Market by End User
      • 8.4.4.1.3Brazil Medical Isotope Market by Application
    • 8.4.4.2Argentina Medical Isotope Market
      • 8.4.4.2.1Argentina Medical Isotope Market by Type
      • 8.4.4.2.2Argentina Medical Isotope Market by End User
      • 8.4.4.2.3Argentina Medical Isotope Market by Application
    • 8.4.4.3UAE Medical Isotope Market
      • 8.4.4.3.1UAE Medical Isotope Market by Type
      • 8.4.4.3.2UAE Medical Isotope Market by End User
      • 8.4.4.3.3UAE Medical Isotope Market by Application
    • 8.4.4.4Saudi Arabia Medical Isotope Market
      • 8.4.4.4.1Saudi Arabia Medical Isotope Market by Type
      • 8.4.4.4.2Saudi Arabia Medical Isotope Market by End User
      • 8.4.4.4.3Saudi Arabia Medical Isotope Market by Application
    • 8.4.4.5South Africa Medical Isotope Market
      • 8.4.4.5.1South Africa Medical Isotope Market by Type
      • 8.4.4.5.2South Africa Medical Isotope Market by End User
      • 8.4.4.5.3South Africa Medical Isotope Market by Application
    • 8.4.4.6Nigeria Medical Isotope Market
      • 8.4.4.6.1Nigeria Medical Isotope Market by Type
      • 8.4.4.6.2Nigeria Medical Isotope Market by End User
      • 8.4.4.6.3Nigeria Medical Isotope Market by Application
    • 8.4.4.7Rest of LAMEA Medical Isotope Market
      • 8.4.4.7.1Rest of LAMEA Medical Isotope Market by Type
      • 8.4.4.7.2Rest of LAMEA Medical Isotope Market by End User
      • 8.4.4.7.3Rest of LAMEA Medical Isotope Market by Application

Chapter 9.Company Profiles

• 9.1Canadian Nuclear Laboratories (Atomic Energy of Canada Limited)
  • 9.1.1Company Overview
  • 9.1.2Recent strategies and developments:
    • 9.1.2.1Partnerships, Collaborations, and Agreements:
  • 9.1.3SWOT Analysis
• 9.2ITM Isotope Technologies Munich SE
  • 9.2.1Company Overview
  • 9.2.2Recent strategies and developments:
    • 9.2.2.1Partnerships, Collaborations, and Agreements:
  • 9.2.3SWOT Analysis
• 9.3ECZACIBASI-MONROL
  • 9.3.1Company Overview
  • 9.3.2Recent strategies and developments:
    • 9.3.2.1Partnerships, Collaborations, and Agreements:
  • 9.3.3SWOT Analysis
• 9.4NorthStar Medical Radioisotopes, LLC
  • 9.4.1Company Overview
  • 9.4.2Recent strategies and developments:
    • 9.4.2.1Partnerships, Collaborations, and Agreements:
  • 9.4.3SWOT Analysis
• 9.5Iba SA
  • 9.5.1Company Overview
  • 9.5.2Financial Analysis
  • 9.5.3Segmental and Regional Analysis
  • 9.5.4Research & Development Expenses
  • 9.5.5SWOT Analysis
• 9.6Mallinckrodt PLC
  • 9.6.1Company Overview
  • 9.6.2Financial Analysis
  • 9.6.3Segmental and Regional Analysis
  • 9.6.4Research & Development Expense
  • 9.6.5SWOT Analysis
• 9.7GE HealthCare Technologies, Inc.
  • 9.7.1Company Overview
  • 9.7.2Financial Analysis
  • 9.7.3Segmental and Regional Analysis
  • 9.7.4Research & Development Expenses
  • 9.7.5Recent strategies and developments:
    • 9.7.5.1Partnerships, Collaborations, and Agreements:
  • 9.7.6SWOT Analysis
• 9.8Nordion Inc. (Sotera Health LLC)
  • 9.8.1Company Overview
  • 9.8.2Financial Analysis
  • 9.8.3Segmental and Regional Analysis
• 9.9Bayer AG
  • 9.9.1Company Overview
  • 9.9.2Financial Analysis
  • 9.9.3Segmental and Regional Analysis
  • 9.9.4Research & Development Expense
  • 9.9.5Recent strategies and developments:
    • 9.9.5.1Partnerships, Collaborations, and Agreements:
  • 9.9.6SWOT Analysis
• 9.10.Siemens Healthineers AG (Siemens AG)
  • 9.10.1Company Overview
  • 9.10.2Financial Analysis
  • 9.10.3Segmental and Regional Analysis
  • 9.10.4Research & Development Expense
  • 9.10.5SWOT Analysis

Chapter 10.Winning Imperatives of medical isotopes Market